Wider use of ranibizumab would cut incidence of blindness

Ranibizumab is a monoclonal antibody fragment used to treat age-related macular degeneration (AMD) and diabetic macular oedema (DMO) — a leading cause of vision loss in working-age adults in the United States.

More… http://www.pharmaceutical-journal.com/news-and-analysis/research-briefing/wider-use-of-ranibizumab-would-cut-incidence-of-blindness-in-diabetic-macular-oedema/20067955.article